- Home
- AQB vs TOVX Comparison
AQB vs TOVX Comparison
Compare AQB & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- TOVX
- Stock Information
- Founded
- AQB 1991
- TOVX 2001
- Country
- AQB United States
- TOVX United States
- Employees
- AQB N/A
- TOVX N/A
- Industry
- AQB
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- AQB
- TOVX Health Care
- Exchange
- AQB Nasdaq
- TOVX Nasdaq
- Market Cap
- AQB 3.0M
- TOVX 3.6M
- IPO Year
- AQB N/A
- TOVX 2006
- Fundamental
- Price
- AQB $0.75
- TOVX $1.28
- Analyst Decision
- AQB Hold
- TOVX Strong Buy
- Analyst Count
- AQB 2
- TOVX 1
- Target Price
- AQB N/A
- TOVX $6.00
- AVG Volume (30 Days)
- AQB 221.1K
- TOVX 247.7K
- Earning Date
- AQB 11-05-2024
- TOVX 03-24-2025
- Dividend Yield
- AQB N/A
- TOVX N/A
- EPS Growth
- AQB N/A
- TOVX N/A
- EPS
- AQB N/A
- TOVX N/A
- Revenue
- AQB $1,258,512.00
- TOVX N/A
- Revenue This Year
- AQB N/A
- TOVX N/A
- Revenue Next Year
- AQB $43.65
- TOVX N/A
- P/E Ratio
- AQB N/A
- TOVX N/A
- Revenue Growth
- AQB N/A
- TOVX N/A
- 52 Week Low
- AQB $0.47
- TOVX $1.14
- 52 Week High
- AQB $2.79
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- AQB 50.10
- TOVX 40.44
- Support Level
- AQB $0.68
- TOVX $1.15
- Resistance Level
- AQB $0.98
- TOVX $1.30
- Average True Range (ATR)
- AQB 0.09
- TOVX 0.09
- MACD
- AQB -0.00
- TOVX -0.04
- Stochastic Oscillator
- AQB 33.93
- TOVX 7.14
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.